The IMF's Understanding series of booklets is designed to acquaint you with treatments and supportive care measures for multiple myeloma. These booklets are also available by mail order and communicate information in a format that is easy to read and understand.
Darzalex® (daratumumab) is a laboratory-made monoclonal antibody that targets a specific single protein on the surface of myeloma cells. Of the four new therapies for myeloma approved in 2015 by the FDA, only Darzalex has single-agent activity and was approved with “breakthrough” status.
An important component of almost all myeloma therapies dexamethasone is a synthetic adrenocortical steroid, also known as glucocorticosteroid or corticosteroid. Dexamethasone is one of the most frequently used medications in the treatment of myeloma (also known as Decadron®, Dexasone®, Diodex®, Hexadrol®, and Maxidex®).
Empliciti® (elotuzumab) is the first immunostimulatory monoclonal antibody approved for the treatment of myeloma. Empliciti enlists immune system cells to attack myeloma. Before reading this booklet, it may be helpful to read another IMF publication, Understanding the Immune System in Myeloma.
As part of a first treatment regimen or at the time of disease relapse, high-dose therapy (HDT) with stem cell rescue (often called “stem cell transplant”) can provide significant remission and survival benefits. This booklet explains the rationale for, and process of, this treatment option for myeloma.
This booklet will help you understand immune system basics. The immune system is extremely complex. It is made up of multiple mechanisms that work together to protect and defend the human body from external threats such as bacteria, viruses, and toxins, and from internal threats such as cancer.
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are not active disease states, but both are precursor states to active myeloma. It is therefore important to understand if, when, and how active myeloma might evolve and what monitoring and/or interventions are appropriate.
Ninlaro® (ixazomib) is the first oral proteasome inhibitor approved by the FDA to treat myeloma. Ninlaro is the third drug in the proteasome inhibitor class that has been approved for myeloma. It is indicated for myeloma patients who have received at least one prior therapy.
Pomalyst® (pomalidomide) is an immuno¬modulatory drug that is used only for patients with relapsed and refractory myeloma who have received at least two prior therapies, including Revlimid® (lenalidomide) and Velcade® (bortezomib), and have demon¬strated disease progression on or within 60 days of completion of the last therapy.